Tag: Economist Intelligence Unit
Latest articles
NICE recommendation for Novartis’ Kisqali® in advanced breast cancer
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Kisqali (ribociclib) in combination with fulvestrant for women with prior endocrine therapy....
New consultancy specialising in healthcare innovation launches
Today sees the launch of Newmarket Strategy, a strategic and technical advisory business specialising in healthcare and life sciences. This new venture brings together three...
Reducing time to market for new COVID-19 vaccines
With the target set to offer a COVID-19 vaccine to a further 17.7 million people in the next five priority groups - including all...
Popular articles
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
New consultancy specialising in healthcare innovation launches
Today sees the launch of Newmarket Strategy, a strategic and technical advisory business specialising in healthcare and life sciences. This new venture brings together three...
NHS prescription charge to increase from 1 April 2021
The NHS prescription charge will increase to £9.35 per prescription item from 1 April 2021 in England, according to the Pharmaceutical Services Negotiating Committee...
Understanding the role of the MSL
Helen Kane surveyed more than 200 medical science liaisons (MSLs) to understand more about their current in-role reality. She gave Pf Magazine exclusive access...